Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis

Jinxia Liu, Jane Macnaughtan, Annarein Kerbert, Theo Portlock, Javier Martínez González, Yi Jin, Frederick Clasen, Abeba Habtesion, Huoyan Ji, Qin Jin, Alexandra Phillips, Francesco De Chiara, Ganesh Ingavle, César Jiménez, Giacomo Zaccherini, Katherine Husi, Miguel Ángel Rodríguez-Gandía, Paúl Cordero, Junpei Soeda, Lynda McConaghy, Jude A. Oben, Karen Church, Jia V. Li, Haifeng Wu, Aarti Jalan, Pere Ginès, Elsa Solà, Simon Eaton, Carrie Morgan, Michał Kowalski, Daniel Green, Amir Gander, Lindsey Edwards, I. Jane Cox, Helena Cortez‐Pinto, Thomas L. Avery, Reiner Wiest, François Durand, Paolo Caraceni, Roberto Elosúa, Joan Vila, Marco Pavesi, Vicente Arroyo, Nathan Davies, Rajeshwar P. Mookerjee, Vı́ctor Vargas, Susan Sandeman, Gautam Mehta, Saeed Shoaie, Julian R. Marchesi, Agustı́n Albillos, Fausto Andreola, Rajiv JalanGut 2024 · DOI

Abstract

Cirrhosis is characterized by a "leaky gut" that allows bacterial toxins to enter the systemic circulation, driving inflammation and organ failure. Current treatments rely heavily on antibiotics, which risk antimicrobial resistance. This study investigates Yaq-001, a novel, non-absorbable carbon bead adsorbent designed to sequester toxins within the gut. Through a multi-tiered approach involving in vitro assays, rodent models of cirrhosis and acute-on-chronic liver failure (ACLF), and a Phase 2 clinical trial (NCT03202498), researchers demonstrated that Yaq-001 significantly reduces liver injury, improves multi-organ function, and is safe and well-tolerated in patients. These findings suggest Yaq-001 is a promising non-antibiotic strategy for managing the gut-liver axis in cirrhosis.

Introduction: The Gut-Liver Axis in Cirrhosis

Advanced liver disease is increasingly recognized as a "gut-centered" pathology. In cirrhosis, the intestinal barrier becomes compromised, leading to "bacterial translocation." Pathogenic molecules, including endotoxins, ammonia, and bile acids, escape the gut and enter the portal and systemic circulation. This influx triggers a cascade of systemic inflammation that can result in life-threatening complications such as hepatic encephalopathy, renal failure, and Acute-on-Chronic Liver Failure (ACLF).

Standard of care often involves antibiotics like rifaximin to reduce the gut bacterial load. However, long-term antibiotic use is problematic due to the potential for microbiome dysbiosis and the emergence of multi-drug resistant organisms. There is a critical need for "sequestration" strategies—therapies that can remove toxins from the intestinal lumen without disrupting the beneficial microbiome or being absorbed into the body.

Yaq-001: A Tailored Adsorption Strategy

Yaq-001 is a synthetic, engineered carbon bead characterized by "tailored porosity." Unlike traditional activated charcoal, Yaq-001 features a specific distribution of micropores (<2nm) and meso-macropores (30-200nm). This architecture allows it to capture a broad spectrum of molecular weights, ranging from small metabolic byproducts like ammonia to larger pro-inflammatory bacterial endotoxins. Because the beads are non-absorbable, they transit through the gastrointestinal tract, "mopping up" toxins and excreting them safely.

Preclinical Evidence and Mechanism

The efficacy of Yaq-001 was validated across multiple experimental platforms:

Animal Models of Cirrhosis and ACLF

Researchers utilized Bile Duct Ligation (BDL) rat models to simulate advanced fibrosis and ACLF, alongside $CCl_4$-injected mouse models for chronic cirrhosis. Treatment with Yaq-001 led to significant improvements in survival and physiological markers:

  • Survival: In the ACLF rat model, Yaq-001 significantly delayed the onset of coma and reduced overall mortality.
  • Portal Hypertension: Treated BDL rats exhibited a significant reduction in portal pressure (11.1 mm Hg vs. 12.4 mm Hg in controls, p=0.025).
  • Biomarkers: Plasma levels of alanine aminotransferase (ALT), ammonia, and D-lactate (a marker of gut permeability) were significantly lowered in treated animals.

Multi-Organ Protection and Transcriptomics

Transcriptomic analysis across the liver, colon, brain, and kidney revealed that Yaq-001 exerts a pleiotropic effect. By stabilizing the gut environment, the drug reduced brain edema and improved renal function (evidenced by lower creatinine levels). This suggests that targeting the gut-liver axis can initiate a systemic "domino effect" of healing.

Microbiome and Barrier Integrity

Contrary to antibiotics, Yaq-001 did not inhibit bacterial growth in vitro. Instead, 16s sequencing showed that it improved microbiome diversity in rats, increasing beneficial taxa like Barnesiella while decreasing pro-inflammatory families. Furthermore, fecal water from treated animals was found to be less toxic to intestinal organoids, confirming that the drug directly protects the intestinal lining from damage.

Clinical Safety: The CARBALIVE-SAFETY Trial

To translate these findings, a Phase 2, double-blind, randomized, placebo-controlled trial was conducted (NCT03202498). The study enrolled 28 patients with stable decompensated cirrhosis across eight European centers. Patients received 4g/day of Yaq-001 or a placebo for three months.

The trial successfully met its primary endpoint of safety and tolerability:

  • Adherence: 93% of the active treatment group completed the full 12-week course.
  • Safety Profile: Adverse events were generally mild, primarily gastrointestinal (e.g., constipation), and occurred at rates comparable to the placebo group. No serious adverse events were attributed to the drug.

Conclusion and Future Directions

Yaq-001 represents a paradigm shift in the management of cirrhosis, moving away from systemic sterilization toward luminal sequestration. By effectively "cleaning" the gut environment, Yaq-001 mitigates the systemic inflammation that drives liver disease progression.

While the preclinical results are robust and the Phase 2 trial confirms safety, limitations remain. The rodent microbiome is not a perfect proxy for humans, and the clinical trial was not powered to demonstrate definitive efficacy. The next phase of development will involve larger, multi-dose Phase 3 trials to confirm if the survival and organ-protective benefits observed in animal models translate into clinical outcomes for patients with cirrhosis.

Trial Registration: NCT03202498

Summary updated

Abstract

NCT03202498.
BibTeX
@inproceedings{liu2024clinical,
  author = {Jinxia Liu and Jane Macnaughtan and Annarein Kerbert and Theo Portlock and Javier Martínez González and Yi Jin and Frederick Clasen and Abeba Habtesion and Huoyan Ji and Qin Jin and Alexandra Phillips and Francesco De Chiara and Ganesh Ingavle and César Jiménez and Giacomo Zaccherini and Katherine Husi and Miguel Ángel Rodríguez-Gandía and Paúl Cordero and Junpei Soeda and Lynda McConaghy and Jude A. Oben and Karen Church and Jia V. Li and Haifeng Wu and Aarti Jalan and Pere Ginès and Elsa Solà and Simon Eaton and Carrie Morgan and Michał Kowalski and Daniel Green and Amir Gander and Lindsey Edwards and I. Jane Cox and Helena Cortez‐Pinto and Thomas L. Avery and Reiner Wiest and François Durand and Paolo Caraceni and Roberto Elosúa and Joan Vila and Marco Pavesi and Vicente Arroyo and Nathan Davies and Rajeshwar P. Mookerjee and Vı́ctor Vargas and Susan Sandeman and Gautam Mehta and Saeed Shoaie and Julian R. Marchesi and Agustı́n Albillos and Fausto Andreola and Rajiv Jalan},
  title = {{Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis}},
  booktitle = {Gut},
  year = {2024},
  doi = {10.1136/gutjnl-2023-330699},
}
Figure